Cero Therapeutics Holdings, Inc.
CERO- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001870404
No open-market purchases or sales by Cero Therapeutics Holdings, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCEROW
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:25 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – |
| Operating expenses | – | – | – | $2.91M |
| Selling, general and administrative | – | – | $2.89M | $2.84M |
| Operating income | – | – | -$2.93M | – |
| Income tax | – | – | $94.8K | $599.2K |
| Net income | -$19.9M | – | -$2.54M | -$667.7K |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023! | FY2022! |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – |
| Cash and equivalents | $1.70M | $1.88M | $96.9K | $475.9K |
| Total current assets | $2.73M | $3.71M | – | $42.4M |
| Property, plant and equipment | $246.1K | $528.5K | – | – |
| Total assets | $3.64M | $6.21M | $8.56M | $42.4M |
| Accounts payable | $7.58M | $4.51M | – | – |
| Total current liabilities | $9.09M | $7.40M | $5.17M | $30.7M |
| Total liabilities | $9.09M | $8.10M | $14.3M | $39.9M |
| Shareholders' equity | -$5.45M | -$1.89M | -$14.2M | -$10.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – |
| Operating cash flow | -$16.1M | – | -$1.52M | -$1.09M |
| Stock-based compensation | $1.10M | – | – | – |
| Dividends paid | $127.1K | – | – | – |
| Share buybacks | – | – | $33.5M | $139.4M |
| Investing cash flow | – | – | -$7.94M | $180.8M |
| Financing cash flow | – | – | -$32.6M | -$138.7M |
| Net change in cash | – | – | -$42.0M | $41.0M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 13, 2026 | 83.3M | +294.8% | SEC |
| Aug 13, 2026 | 71.6M | +5,842.5% | SEC |
| May 14, 2026 | 45.1M | +484.2% | SEC |
| Apr 14, 2026 | 36.8M | +583.7% | SEC |
| Nov 19, 2025 | 21.1M | −86.0% | SEC |
| Aug 21, 2025 | 1.21M | −97.6% | SEC |
| May 14, 2025 | 7.72M | −48.7% | SEC |
| Apr 24, 2025 | 5.58M | −63.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.